Nan Zhou Yuhong Chen Qian Huang Lili Jiang Hu Liao Hongfeng Gou You Lu Guowei Che Yan Zhang
10.3389/fimmu.2023.1111325
Front Immunol
2023 Feb 22;14:1111325.
case report immunotherapy lymphocyte infiltration neoadjuvant therapy pathological complete response programmed cell death-1 (pd-1) small cell lung cancer tislelizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/36911701/
Carcinoma, Non-Small-Cell Lung / drug therapy Lung Neoplasms / pathology Small Cell Lung Carcinoma / drug therapy
Carcinoma, Non-Small-Cell Lung / drug therapy Lung Neoplasms / pathology Small Cell Lung Carcinoma / drug therapy Review Case Reports Research Support, Non-U.S. Gov't Antineoplastic Combined Chemotherapy Protocols / therapeutic use Carboplatin / therapeutic use Etoposide / therapeutic use Humans Neoadjuvant Therapy Carboplatin tislelizumab Etoposide
PMC9992202
36911701
Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
2023